Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Dieter SM, Lovecchio D, Pataskar A, Zowada MK, et al. Oncogene 2022 Jul 7. pii: 10.1038/s41388-022-02400.

Read + Share

Amedeo Smart

Independent Medical Education

Dieter SM, Lovecchio D, Pataskar A, Zowada MK, et al. Suppression of heparan sulfation re-sensitizes YAP1-driven melanoma to MAPK pathway inhibitors. Oncogene 2022 Jul 7. pii: 10.1038/s41388-022-02400.
PMID: 35798875